Investing.com - Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have turned sharply lower in the after hours session following the company’s announcement that the U.S. Food and Drug Administration (FDA) has requested more detailed information about the company's proposed post-marketing study for its Hepatitis B Vaccine, based on feedback received from the FDA's Vaccines and Related Biological Products Advisory Committee during a meeting on July 28, 2017.
Dynavax shares had previously popped on July 31 after the Food and Drug Administration advisory committee voted in favor of its Hepatitis B vaccine.